Biogen/ Eisai Alzheimer’s therapy Leqembi approved in Japan
juststock/iStock via Getty Images

Biogen (NASDAQ:BIIB) and its partner Eisai Co., Ltd. (OTCPK:ESALF) announced Monday that Japan had approved their amyloid-targeting monoclonal antibody Leqembi for patients with Alzheimer's disease.
Accordingly, the intravenous infusion, also known as Lecanemab, will be available in the country to slow mild cognitive impairment and dementia linked to Alzheimer's.

The Asian country is the second nation to approve Leqembi after the U.S. granted it traditional approval as a treatment for the memory-robbing decision in July.
Biogen (BIIB) and Eisai (OTCPK:ESALF) will jointly promote and commercialize the treatment in Japan, with the latter distributing the product.
Japanese authorities used data from Eisai's (OTCPK:ESALF) Phase 3 Clarity AD clinical trial to arrive at their decision.
Based on a measure called Clinical Dementia Rating Sum of Boxes (CDR-SB), the global trial met its primary endpoint as Leqembi reduced the rate of dementia progression by 27% at 18 months compared to placebo.
Brain hemorrhages, edema, and headaches were among the most common adverse events.
Eisai (OTCPK:ESAIY) will run a post-marketing survey to collect data from a certain number of patients as a condition for approval.



More on Biogen, Eisai, etc.

Eisai: Lumpy Rollout Of Leqembi, Economic Value Hard To Ascertain (Rating Downgrade)
Biogen: Leqembi Could Boost Prospects Until Acquisition Comes Into Play
Biogen Q2 2023 Analysis: Reata Acquisition, Financials, And Alzheimer's Prospects
Eisai: Looking To Upside Targets Following Leqembi Full Approval
Reata shareholders clear buyout deal with Biogen